Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Repeated CBD Administration and Cannabis Outcomes

Hannah Harris · with National Institute on Drug Abuse (NIDA) · NCT07434895

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
23
US sites recruiting
1
Study start
August 5, 2026
Record last updated
August 12, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Being studied: Cannabidiol, Medium Dose; Cannabidiol, Higher Dose; Active Inhaled Cannabis; Placebo Cannabidiol; Placebo Inhaled Cannabis

Conditions: Cannabis; Abuse Liability; Experimental Pain in Healthy Human Participants

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • English-speaking, literate adults,
  • Male or female,
  • Between the ages of 18-55,
  • Body Mass Index from 18.5-32.0 kg/m2,
  • Not currently seeking treatment for cannabis or drug use,
  • Able to provide written informed consent and perform all study procedures,
  • If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
  • Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
  • Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.

Exclusion Criteria

  • Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
  • Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),
  • Current or past history of major psychiatric disorder that would limit ability to participate in the study,
  • Use of cannabis exclusively for medical reasons (no recreational use reported),
  • Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
  • Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
  • Clinically significant abnormal ECG (as determined by study physician/cardiologist),
  • Clinically significant abnormal laboratory findings,
  • History of seizure disorder,
  • Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
  • Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).

Recruiting US locations

  • University of Kentucky

    Lexington, KY 40508

    Site contact: Paul A Nuzzo, M.A. · 859-323-0002 · pnuzz2@email.uky.edu

Study contacts (from the official record)

  • Paul A Nuzzo, M.A. · 859-323-0002 · pnuzz2@email.uky.edu